James W Murrough
Icahn School of Medicine · Icahn School of Medicine at Mount Sinai
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
8
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
3 more share only the name and are not shown
Trial papers
42
PubMed author-name match
Trials
Studies that name James W Murrough as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07908563 · Dupilumab in Major Depressive DisorderIcahn School of Medicine at Mount Sinai · recruiting · Major Depressive Disorder · principal investigator
- Ph2NCT04979910 · Targeting IL-17A for Treatment-Resistant DepressionIcahn School of Medicine at Mount Sinai · completed · Major Depressive Disorder · principal investigator
- Ph2NCT04827901 · XEN1101 for Major Depressive DisorderJames Murrough · completed · Major Depressive Disorder · principal investigator
- Ph2NCT01880593 · Ketamine Plus Lithium in Treatment-Resistant DepressionIcahn School of Medicine at Mount Sinai · completed · Depression · principal investigator
- N/ANCT01309581 · Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in DepressionJames Murrough · terminated · Major Depression, Bipolar Depression · principal investigator
- N/ANCT01304147 · Intranasal Ketamine in Treatment-Resistant DepressionJames Murrough · completed · Major Depressive Disorder · principal investigator
- Ph4NCT00947791 · Treatment Study of Bipolar DepressionIcahn School of Medicine at Mount Sinai · terminated · Bipolar Disorder · principal investigator
- Ph1NCT00548964 · Continuation Ketamine in Major DepressionJames Murrough · completed · Major Depressive Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRIR01MH134045 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2023 to 2026 · $765,927 awarded in 2026Same name and institution; not confirmed by an ID
- Neuroimmune Mechanisms of Depression and AnhedoniaR01MH141038 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2026 · $839,815 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Pharmacology and Target Validation of BDPP for Stress-Related DisordersU19AT010835 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2020 to 2024 · $395,598 awarded in 2024Same name and institution; not confirmed by an ID
- Developing Neuronal KCNQ Channel Modulators for Mood DisordersR33MH111932 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2021 to 2023 · $776,711 awarded in 2023Grant number is on one of their registry trials
- Phase 1 Translational Diabetes Research Using The DYRK1A inhibitor, HarmineR01DK128242 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2022 to 2023 · $338,000 awarded in 2023Same name and institution; not confirmed by an ID
- Transdiagnostic Multimodal 7 Tesla MRI of the Locus Coeruleus in Human Pathological AnxietyR01MH116953 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2019 to 2023 · $520,443 awarded in 2023Same name and institution; not confirmed by an ID
- Developing Neuronal KCNQ Channel Modulators for Mood DisordersR61MH111932 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2017 to 2018 · $802,607 awarded in 2018Same name and institution; not confirmed by an ID
- Inflammatory and neurocircuit mechanisms of anhedonia in human depressionR21MH109771 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2016 to 2017 · $254,250 awarded in 2017Same name and institution; not confirmed by an ID
- Functional MRI Studies of Emotion in Depression and Rapid Antidepressant ResponseK23MH094707 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2011 to 2015 · $176,518 awarded in 2015Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:25 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.Am J Psychiatry · 2013951 citationsRCR 36.0
- Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.Biol Psychiatry · 2013613 citationsRCR 22.6
- Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.Biol Psychiatry · 2010538 citationsRCR 16.2
- Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.JAMA Psychiatry · 2014427 citationsRCR 16.6
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.Am J Psychiatry · 2016413 citationsRCR 18.7
- A randomized controlled trial of intranasal ketamine in major depressive disorder.Biol Psychiatry · 2014365 citationsRCR 14.0
- Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.Depress Anxiety · 2014266 citationsRCR 11.0
- 249 citationsRCR 10.1
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.N Engl J Med · 2023230 citationsRCR 33.3
- Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.Int J Neuropsychopharmacol · 2010206 citationsRCR 6.4